Skip to main content

Table 1 Baseline demographic, clinical and tumor characteristics of the whole patient cohort before TACE treatment

From: TACE performed in patients with a single nodule of Hepatocellular Carcinoma

Variable

Study population (n = 148)

Gender male, n (%)

104 (70)

Age, median (years) (range)

64 (36–84)

Cause of disease, n (%)

 

  HBV

14 (9)

  HCV

85 (57)

  Alcohol

19 (13)

  Multiple etiologies

17 (12)

  Unknown

12 (8)

  Other

1 (1)

Lesion location, n (%)

 

  Right lobe

110 (74)

  Left lobe

38 (26)

TACE Selectivity, n (%)

 

  Lobar

10 (7)

  Selective

73 (49)

  Superselective

65 (44)

Tumor size, median (cm) (range)

3.0 (0.8 – 15.0)

Milan criteria within, n (%) *

135 (91)

Portal vein thrombosis, n (%)

 

  Absent

131 (88)

  Segmental bland thrombosis

4 (3)

  Lobar bland thrombosis

13 (9)

Serum AFP, median (ng/mL) (range)

14.5 (1.0 – 39576.0)

Ascites, n (%)

 

  Absent

120 (81)

  Slight – Moderate

23 (16)

  Severe – Refractory

5 (3)

Encephalopathy, n (%)

 

  Absent

145 (98)

  Slight

3 (2)

Serum total bilirubin, median (mg/dL) (range)

1.34 (0.30 – 10.67)

Serum albumin, median (g/dL) (range)

3.60 (2.10 – 5.00)

Serum INR, median (range)

1.28 (1.00 – 1.97)

Hepatic function, n (%)

 

  CPT-A

92 (62)

  CPT-B

56 (38)

Performance status, n (%)

 

  0

133 (90)

  1

15 (10)

BCLC stage, n (%)

 

  0

16 (11)

  A

104 (70)

  B

13 (9)

  C

15 (10)

MELD score, median (range)

11 (6 – 24)

  1. *patients with HCC ≤5 cm.
  2. Abbreviations: HBV hepatits B virus, HCV hepatitis C virus, TACE transarterial chemoembolization, AFP Alpha-fetoprotein, INR international normalized ratio, CPT Child-Pugh-Turcotte score, BCLC Barcelona Clinic Liver Cancer, MELD Model for end stage liver disease.